Iranian Red Crescent Medical Journal

Published by: Kowsar

Clinical Lipid Control Success Rate Before and After Percutaneous Coronary Intervention in Iran; a Single Center Study

Seyed Kianoosh Hosseini 1 , Maryam Tahvildari 2 , Mohammad Javad Alemzadeh Ansari 1 , Manouchehr Nakhjavani 3 , * , Alireza Esteghamati 3 and Masoumeh Lotfi Tokaldany 4
Authors Information
1 Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, IR Iran.
2 Tehran University of Medical Sciences, Tehran, IR Iran.
3 Endocrinology and Metabolism Research Centre (EMRC), Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, IR Iran.
4 Research Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: June 5, 2013, 15 (6); 467-472
  • Published Online: June 5, 2013
  • Article Type: Research Article
  • Received: May 6, 2012
  • Revised: April 12, 2013
  • Accepted: April 25, 2013
  • DOI: 10.5812/ircmj.3370

To Cite: Hosseini S K, Tahvildari M, Alemzadeh Ansari M J, Nakhjavani M, Esteghamati A, et al. Clinical Lipid Control Success Rate Before and After Percutaneous Coronary Intervention in Iran; a Single Center Study, Iran Red Crescent Med J. 2013 ; 15(6):467-472. doi: 10.5812/ircmj.3370.

Copyright © 2013, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Chrysant SG. Stopping the cardiovascular disease continuum: Focus on prevention. World J Cardiol. 2010; 2(3): 43-9[DOI][PubMed]
  • 2. Arsenault BJ, Rana JS, Stroes ES, Despres JP, Shah PK, Kastelein JJ, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol. 2009; 55(1): 35-41[DOI][PubMed]
  • 3. Eyre H, Kahn R, Robertson RM, Clark NG, Doyle C, Hong Y, et al. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation. 2004; 109(25): 3244-55[DOI][PubMed]
  • 4. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004; 89(6): 2595-600[DOI][PubMed]
  • 5. Pres D, Gasior M, Lekston A, Gierlotka M, Hawranek M, Tajstra M, et al. Relationship between low-density lipoprotein cholesterol level on admission and in-hospital mortality in patients with ST-segment elevation myocardial infarction, with or without diabetes, treated with percutaneous coronary intervention. Kardiol Pol. 2010; 68(9): 1005-12[PubMed]
  • 6. Petrella RJ, Merikle E, Jones J. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis. Clin Ther. 2007; 29(4): 742-50[DOI][PubMed]
  • 7. Cooke CE, Hammerash WJ, Jr. Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland-based health maintenance organization. Clin Ther. 2006; 28(4): 591-9[DOI][PubMed]
  • 8. Stacy TA, Egger A. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs. J Manag Care Pharm. 2006; 12(9): 745-51[PubMed]
  • 9. Petrella RJ, Merikle E. A retrospective analysis of the prevalence and treatment of hypertension and dyslipidemia in Southwestern Ontario, Canada. Clin Ther. 2008; 30(6): 1145-54[DOI][PubMed]
  • 10. Goff DC, Jr, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, et al. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation. 2006; 113(5): 647-56[DOI][PubMed]
  • 11. Wilt TJ, Bloomfield HE, MacDonald R, Nelson D, Rutks I, Ho M, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med. 2004; 164(13): 1427-36[DOI][PubMed]
  • 12. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999; 100(10): 1134-46[PubMed]
  • 13. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992; 85(1): 37-45[PubMed]
  • 14. Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz Praventivmed. 2002; 47(6): 408-26[PubMed]
  • 15. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J. 2008; 156(1): 112-9[DOI][PubMed]
  • 16. Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med. 2009; 169(6): 572-8[DOI][PubMed]
  • 17. Esteghamati A, Abbasi M, Nakhjavani M, Yousefizadeh A, Basa AP, Afshar H. Prevalence of diabetes and other cardiovascular risk factors in an Iranian population with acute coronary syndrome. Cardiovasc Diabetol. 2006; 5: 15[DOI][PubMed]
  • 18. Hosseini SK, Mehrpooya M. Lipid Control before CABG and Its Association with In-Hospital Mortality. Iran Red Crescent Med J. 2011; 13(2): 106-11[PubMed]
  • 19. Khashayar P, Mohagheghi A. The correlation between dyslipidemia and coronary artery disease based on angiographic findings in an Iranian population. Acta Med Indones. 2010; 42(2): 82-5[PubMed]
  • 20. Krauss RM, Mangravite LM, Smith JD, Medina MW, Wang D, Guo X, et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation. 2008; 117(12): 1537-44[DOI][PubMed]
  • 21. Cruz I, Serna C, Real J, Galindo G, Gasco E, Galvan L. Ischemic heart disease and primary care: identifying gender-related differences. An observational study. BMC Fam Pract. 2008; 9: 60[DOI][PubMed]
  • 22. Nakhjavani M, Esteghamati AR, Heshmat F Esfahanian AR. Dyslipidemia in type 2 diabetes mellitus: More atherogenic lipid profile in women. Acta Medica Iranica. 2006; 44(2)
  • 23. Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm. 2008; 14(8 Suppl)-28[PubMed]
  • 24. Rubins HB, Collins D, Robins SJ. The VA HDL intervention trial: clinical implications. Eur Heart J. 2000; 21(14): 1113-5[DOI][PubMed]
  • 25. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350(15): 1495-504[DOI][PubMed]
  • 26. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl. 2004; 5(3): 81-7[DOI][PubMed]
  • 27. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs. 2004; 64 Suppl 2: 43-60[PubMed]
  • 28. Suadicani P, Hein HO, Gyntelberg F. Antihypertensive treatment, high triglycerides, and low high-density lipoprotein cholesterol and risk of ischemic heart disease mortality: a 16-year follow-up in the Copenhagen male study. Metab Syndr Relat Disord. 2010; 8(3): 215-22[DOI][PubMed]
  • 29. Hadaegh F, Khalili D, Ghasemi A, Tohidi M, Sheikholeslami F, Azizi F. Triglyceride/HDL-cholesterol ratio is an independent predictor for coronary heart disease in a population of Iranian men. Nutr Metab Cardiovasc Dis. 2009; 19(6): 401-8[DOI][PubMed]
  • 30. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. High triglycerides/low high-density lipoprotein cholesterol, ischemic electrocardiogram changes, and risk of ischemic heart disease. Am Heart J. 2003; 145(1): 103-8[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments